Shutterstock
Viral vector-based gene therapies hold immense promise for treating a multitude of diseases. However, their widespread adoption has been hindered by inefficient manufacturing methods and the absence of established standardised processes, resulting in high costs and limited accessibility for patients. Cytiva is bringing solutions to these challenges with its new ELEVECTA cell lines.
Emmanuel Abate, President Genomic Medicine, Cytiva says: “We are relentless in our pursuit of bringing life changing therapies to patients faster. To make gene therapy a realistic option for more patients, we need to be able to standardise its manufacturing. We’ve gone to the heart of the process by creating viral vector cell lines that will make a big impact to developers of gene therapies.”
The three lines comprehensively meet the distinct objectives of various therapeutic programs with the ability to transition between cell lines as needs evolve and can be paired with Cytiva’s established cell culture media offering:
- A transient cell line that provides speed and flexibility enabling researchers to easily integrate it into their existing workflow. This cell line is paired with a new cell culture medium, HyClone prime expression designed to enhance performance. Both the cell line and corresponding media will be available soon.
- A packaging cell line that eases the screening of genes of interest while enabling efficiencies across clinical stages and assets. This line is available now in selected formulations.
- A producer cell line that stably integrates all four required genes for AAV production; production starts by simply adding an induction agent, no transfection is needed. This line is available now to be customised to each individual therapy.